{"groups":[{"description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles","id":"FG000","title":"Treatment (Pembrolizumab)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Disease progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"Cycle 1"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"Cycle 8"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Stage 1"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"FDA guidance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"Cycle 1"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"Cycle 8"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Stage 2"}],"preAssignmentDetails":"20 participants were consented. 13 participants were treated at MD Anderson Cancer Center. An additional participant started stage 2 that did not participate in Stage 1\"","recruitmentDetails":"Enrollment period was between July 2016 and August 2017"}